Healthcare
April 3, 2018 / 5:11 AM / 10 months ago

BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod

1 Min Read

April 3 (Reuters) - ARGENX NV:

* ‍TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below